SCHEMBL24252662

SCHEMBL24252662

COc1c(-c2ccc3c(N)nnc(C)c3c2)cc(B(O)O)cc1C(F)(F)F

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.31
SCN5A Q14524 1/20 0.31
SOS1 Q07889 1/20 0.31
HSD11B1 P28845 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451527 1.00 SCN9A (0.31) SCN9ASCN5ASOS1HSD11B1
SCHEMBL26771147 0.93 SCN9A (0.31) SCN9ASCN5ASOS1
SCHEMBL24252685 0.86 PDGFRB (0.32)
SCHEMBL24252659 0.86 DHFR (0.31)
SCHEMBL24252277 0.84 TRPA1 (0.34) SCN9ASCN5A
Trifluoroacetic Acid SCHEMBL30453252 0.83 PDGFRB (0.32) SCN9A
Trifluoroacetic Acid SCHEMBL29015411 0.83 PDGFRB (0.32) SCN9A
Formic Acid SCHEMBL25267136 0.81
Formic Acid SCHEMBL30451453 0.81
SCHEMBL24252735 0.80 SOS1 (0.35) SCN9ASOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SCN9A 3732/4885SCN5A 3532/4885SOS1 4482/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SCN9A 3732/4885SCN5A 3532/4885SOS1 4482/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 SCN9A 3732/4885SCN5A 3532/4885SOS1 4482/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH SCN9A 1089/4885SCN5A 482/4885SOS1 4201/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 SCN9A 601/4885SCN5A 301/4885SOS1 1649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.